Furthering the evidence-based management of dermatologic effects of EGFR inhibitor therapy

作者: Supriya Koya , Chandra Kumar Shanmugam , Venkat Rao Katkoori , Upender Manne , James A. Posey

DOI: 10.1007/S11888-009-0034-5

关键词:

摘要:

参考文章(6)
E. Van Cutsem, R.J. Mayer, P. Gold, P. Stella, A. Cohn, A. Pippas, P. Windt, P. Molloy, H.J. Lenz, 279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin Ejc Supplements. ,vol. 2, pp. 85- 86 ,(2004) , 10.1016/S1359-6349(04)80287-8
Susan L. Boone, Alfred Rademaker, Dachao Liu, Carmen Pfeiffer, David J. Mauro, Mario E. Lacouture, Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. ,vol. 72, pp. 152- 159 ,(2007) , 10.1159/000112795
Alon Scope, Anna Liza C. Agero, Stephen W. Dusza, Patricia L. Myskowski, Jocelyn A. Lieb, Leonard Saltz, Nancy E. Kemeny, Allan C. Halpern, Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption Journal of Clinical Oncology. ,vol. 25, pp. 5390- 5396 ,(2007) , 10.1200/JCO.2007.12.6987
Thomas J. Lynch, Ed S. Kim, Beth Eaby, Jody Garey, Dennis P. West, Mario E. Lacouture, Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management Oncologist. ,vol. 12, pp. 610- 621 ,(2007) , 10.1634/THEONCOLOGIST.12-5-610
DO Patricia Lorusso, Toward evidence-based management of the dermatologic effects of EGFR inhibitors. Oncology. ,vol. 23, pp. 186- 194 ,(2009)
S. Tejpar, M. Peeters, Y. Humblet, J. B. Vermorken, G. De Hertogh, W. De Roock, J. Nippgen, A. von Heydebreck, C. Stroh, E. Van Cutsem, Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) Journal of Clinical Oncology. ,vol. 26, pp. 4001- 4001 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4001